RU2015126015A - Новые улавливатели в лечении макулодистрофии - Google Patents
Новые улавливатели в лечении макулодистрофии Download PDFInfo
- Publication number
- RU2015126015A RU2015126015A RU2015126015A RU2015126015A RU2015126015A RU 2015126015 A RU2015126015 A RU 2015126015A RU 2015126015 A RU2015126015 A RU 2015126015A RU 2015126015 A RU2015126015 A RU 2015126015A RU 2015126015 A RU2015126015 A RU 2015126015A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- cycloalkyl
- compound according
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 150000001721 carbon Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 210000001525 retina Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000011506 response to oxidative stress Effects 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756778P | 2013-01-25 | 2013-01-25 | |
| US61/756,778 | 2013-01-25 | ||
| PCT/US2014/012356 WO2014116593A1 (en) | 2013-01-25 | 2014-01-21 | Novel traps in the treatment of macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015126015A true RU2015126015A (ru) | 2017-03-03 |
Family
ID=51227964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015126015A RU2015126015A (ru) | 2013-01-25 | 2014-01-21 | Новые улавливатели в лечении макулодистрофии |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10111862B2 (enExample) |
| EP (1) | EP2948436A4 (enExample) |
| JP (1) | JP6266023B2 (enExample) |
| KR (1) | KR20150120380A (enExample) |
| CN (1) | CN105228989A (enExample) |
| AU (1) | AU2014209585A1 (enExample) |
| CA (1) | CA2898869A1 (enExample) |
| HK (1) | HK1217490A1 (enExample) |
| IL (1) | IL239736A0 (enExample) |
| MX (1) | MX2015009444A (enExample) |
| RU (1) | RU2015126015A (enExample) |
| SG (1) | SG11201505599YA (enExample) |
| WO (1) | WO2014116593A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| HK1217325A1 (zh) | 2012-12-20 | 2017-01-06 | 奥尔德拉医疗公司 | 迫位原醇 |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| WO2016021706A1 (ja) * | 2014-08-08 | 2016-02-11 | カズマパートナーズ株式会社 | 縮合複素環化合物 |
| CN108135907A (zh) | 2015-08-21 | 2018-06-08 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| MX2018010292A (es) | 2016-02-28 | 2018-09-27 | Aldeyra Therapeutics Inc | Tratamiento de condiciones oculares alergicas con ciclodextrinas. |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| MX2022002652A (es) * | 2019-09-09 | 2022-04-06 | Univ Pittsburgh Commonwealth Sys Higher Education | Metodos para restaurar la funcion lisosomal de celulas epiteliales de pigmento retiniano mediante activacion de tfeb. |
| WO2021136244A1 (zh) * | 2019-12-30 | 2021-07-08 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| US5742954A (en) | 1996-11-22 | 1998-04-28 | Softub, Inc. | Electrically powered spa jet unit |
| EP0980362B1 (de) | 1997-05-02 | 2006-08-16 | Schering Aktiengesellschaft | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| EP1080068A1 (en) | 1998-03-12 | 2001-03-07 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| WO2001041757A1 (en) | 1999-12-10 | 2001-06-14 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20040242704A1 (en) | 2003-03-14 | 2004-12-02 | University Of Washington, Techtransfer - Invention Licensing | Stabilized mutant opsin proteins |
| EP2292239A3 (en) | 2003-04-18 | 2011-03-30 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
| AU2004293105B2 (en) | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| AU2005215778B2 (en) | 2004-02-17 | 2009-03-12 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| US20070287716A1 (en) | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| BRPI0722382A2 (pt) | 2006-04-14 | 2012-06-05 | Prana Biotechnology Ltd | compostos úteis para o tratamento de cáncer |
| CA2658793A1 (en) | 2006-07-25 | 2008-02-07 | Daniel Dumas | Quinoline derivatives |
| TW200922548A (en) | 2007-10-05 | 2009-06-01 | Acucela Inc | Alkoxy compounds for disease treatment |
| WO2010019606A1 (en) * | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| WO2011072141A1 (en) * | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2824779C (en) | 2011-01-12 | 2020-01-14 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| EP2670439B1 (en) | 2011-01-31 | 2019-03-13 | PVAC Medical Technologies Ltd. | Active principle for mitigating undesired medical conditions |
| HK1217325A1 (zh) | 2012-12-20 | 2017-01-06 | 奥尔德拉医疗公司 | 迫位原醇 |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
-
2014
- 2014-01-21 HK HK16105524.6A patent/HK1217490A1/zh unknown
- 2014-01-21 KR KR1020157022937A patent/KR20150120380A/ko not_active Withdrawn
- 2014-01-21 JP JP2015555214A patent/JP6266023B2/ja not_active Expired - Fee Related
- 2014-01-21 CA CA2898869A patent/CA2898869A1/en not_active Abandoned
- 2014-01-21 WO PCT/US2014/012356 patent/WO2014116593A1/en not_active Ceased
- 2014-01-21 RU RU2015126015A patent/RU2015126015A/ru not_active Application Discontinuation
- 2014-01-21 CN CN201480005973.2A patent/CN105228989A/zh active Pending
- 2014-01-21 SG SG11201505599YA patent/SG11201505599YA/en unknown
- 2014-01-21 US US14/760,041 patent/US10111862B2/en active Active
- 2014-01-21 MX MX2015009444A patent/MX2015009444A/es unknown
- 2014-01-21 AU AU2014209585A patent/AU2014209585A1/en not_active Abandoned
- 2014-01-21 EP EP14743787.5A patent/EP2948436A4/en not_active Withdrawn
-
2015
- 2015-07-01 IL IL239736A patent/IL239736A0/en unknown
-
2018
- 2018-10-23 US US16/168,309 patent/US20190125729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6266023B2 (ja) | 2018-01-24 |
| US20190125729A1 (en) | 2019-05-02 |
| IL239736A0 (en) | 2015-08-31 |
| AU2014209585A1 (en) | 2015-07-23 |
| HK1217490A1 (zh) | 2017-01-13 |
| CA2898869A1 (en) | 2014-07-31 |
| JP2016505637A (ja) | 2016-02-25 |
| CN105228989A (zh) | 2016-01-06 |
| US20150344447A1 (en) | 2015-12-03 |
| EP2948436A4 (en) | 2016-07-13 |
| MX2015009444A (es) | 2016-04-15 |
| US10111862B2 (en) | 2018-10-30 |
| SG11201505599YA (en) | 2015-08-28 |
| EP2948436A1 (en) | 2015-12-02 |
| KR20150120380A (ko) | 2015-10-27 |
| WO2014116593A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505637A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2015120478A (ru) | Пери-карбинолы | |
| RU2015129546A (ru) | Нейроактивные 19-алкокси-17-замещенные стероиды, их пролекарства и способы лечения с их применением | |
| JP2016525121A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2015517574A5 (enExample) | ||
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| RU2016105436A (ru) | Нейроактивные стероиды, композиции и их использование | |
| JP2016528301A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015516427A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| RU2016138676A (ru) | Ингибиторы усилителя zeste гомолога 2 | |
| PH12020550452A1 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180504 |